Elevating tomorrow’s standard of cancer care today
INTRODUCING ABALYTICS ONCOLOGY
10 million people die from cancer every year. It remains the cause of every sixth death. At Abalytics Oncology, our vision is to redefine the standard of cancer care in the 21st century.
Solid tumors remain an unsolved problem today. Our focus on some of the hardest-to-treat patients is just the beginning. As we demonstrate results, learn, and innovate, we plan to broaden the scope of our efforts to ensure a comprehensive impact on cancer care.
Core Values
How do you act in the face of an existential threat? Where do you choose to focus?
At Abalytics Oncology, we weigh decisions against our values before we act, and then again after.
Overall survival
Quality of life
Greater Understanding
Resource Optimization
Expanded Access
Our Founders
Akshay Paintal
CEO
Shay combines a track record of successful computational antibody design with a decade of experience founding data-driven companies. He is the inventor of Omoprubart and has executed on over 15 computational antibody design and development programs including TY027. Shay has developed computational antibody design systems at the Sasisekharan Lab in MIT’s Koch Institute for Integrative Cancer Research and built diverse technology solutions for government and big pharma clients exploring applications of artificial intelligence. An ex-Deloitte technology consultant, Shay holds a Bachelor of Science in Chemical and Biomolecular Engineering from Johns Hopkins University.
Manish Potti
Chief Business Officer
Manish has a track record of execution in the biopharmaceutical industry. He was the Chief Business Officer of Shinkei Therapeutics, a CNS focused company. He was previously the President and co- founder of Innogenix Pharmaceuticals. At Innogenix, Manish took a brownfield project through FDA facility approval, directed the R&D strategy, in-licensed assets, and grew the revenue to a stable base. He was also the head of business development of Epic Pharma, where he led the sale process of the company to Humanwell Healthcare of China in 2016. Since 2016, he has been actively investing and managing portfolio companies in biotech, spec pharma, and medtech. Manish has overseen R&D,…
Approach
We develop combination therapies to tackle cancer immune resistance
ABALYTICS ONCOLOGY COMBINATION THERAPIES
Immune Checkpoint Inhibitors
Antibody Drug Conjugates
Targeted Therapies
MECHANISMS OF CANCER IMMUNE
RESISTANCE
Immune Suppression
Blockage and downregulation of immune response
T cell Exhaustion
Body loses key line of
defense
Immune Evasion
Tumor cells are invisible to the
immune system
SUCCESS OUTCOMES
Tumor shrinkage
Durable responses
Overall survival
We use computational antibody design and biomolecular engineering to develop better treatments
Abalytics Stands for Antibody Data Analytics
Abalytics Intelligence
While most drug development fails from the beginning, we start with what works.
Real-world information, in real-time
Artificial Intelligence generates infinite options, which human intelligence evolved to constrain.
Abalytics Algorithms
Target selection
Antibody design
Drug discovery
Translational Models
Companion diagnostics
Treatment Decisions
Abalytics Combination Therapies
Holistic approaches to tackling key mechanisms
of cancer immune resistance
Immune Checkpoint Inhibitors
Antibody Drug Conjugates
Targeted Therapies
Pipeline
ABAO2 paves the way for a risk-balanced pipeline of best-in-class molecules
Program
Discovery
IND-Enabling Studies
Status
ABAO2 Anti-CTLA-4
CMC Ready
ABAO1 Anti-PD-1
CMC Ready
ABAO3 ICI
R&D
ABAO4 ICI
R&D
R&D
R&D
Contact us
Connect with us about reshaping the future of cancer care today.
